GUNS Trial Updates: Precision Neoadjuvant Approaches for High-Risk Prostate Cancer

Date Posted
Dr. Gleave

The Vancouver Prostate Centre is proud to highlight new findings from the GUNS trial, an adaptive neoadjuvant study designed for men with high-volume, high-grade prostate cancer.

Led by Dr. Martin E. Gleave, CM, MD, FRCSC, FACS, British Columbia Leadership Chair, Distinguished Professor, and Director, Vancouver Prostate Centre, GUNS sequences needle biopsies during an eight-week apalutamide-based ARPI doublet to assign patients to biomarker-directed treatment subprotocols. Early results show that tailoring therapy based on tumor genomics can enhance response rates, particularly for patients with aggressive AR-associated and tumor suppressor gene alterations.
This trial exemplifies a precision-oncology approach, using tumor biology to guide systemic therapy decisions and advance future treatment strategies in prostate cancer.